Shares of Dendreon shed most of their value Monday before markets opened, sinking 67 cents to 27 cents. The stock had slipped below $1 earlier this fall and has tumbled most of this year after closing 2013 at $2.99.
(Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate ... The Seattle-based company's stock was trading at $3.30 before the bell.
The company did not immediately respond to a request for comments. SHARE ACTION: In morning trading Dendreon stock lost 7 cents, or 2.6 percent, to $2.51 in late morning trading. Shares gained as much as 9.2 percent during the day Tuesday. They closed up 8 ...
Dendreon's stock price took a hit, as investors tried to second-guess which way the winds were blowing at the agency. But as the previous panel had voted for approval with clinical data that fell short of statistical significance, it seemed unlikely that ...
Nature · 1y
DNDN) today announced that management will present at the following three investor conferences this month. Cowen and Company 30th Annual Health Care Conference, Boston, MA Tuesday, March 9, 2010 4:30 p.m. ET ROTH 22nd Annual OC …
4-Traders · 8y
Investors can view all of the daily updates for free by visiting: http://stockpreacher.com/StockTalk Today's Trade Alerts include: Broadwind Energy, Inc. , BHP Billiton Ltd. , Citigroup Inc. , Candela Corporation , Dendreon Corporation , eBay Inc ...
The first cancer vaccine, known as Provenge ... are being developed by other companies around the world. But with their stock skyrocketing following the announcement, right now, Dendreon has much to celebrate.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights from Tuesday’s Analyst Blog: Is Dendreon Up for Sale? Dendreon Corp.’s ( DNDN- Free Report) share price jumped more than …
SEATTLE, July 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a ...
SHARE ACTION: Dendreon shares lost 47 cents, or 7 percent, to $6.29 in midday trading. The stock is down 42 percent since May 7, when the Seattle company reported its first-quarter results. Johnson & Johnson shares rose 30 cents to $62.08 and Medivation ...